NCT00592176

The Effect of Bevacizumab (Avastin) on Pterygium

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: University of Alabama at Birmingham · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether local injection of bevacizumab might halt and or cause regression of pterygium growth. This may enable earlier treatment and prevention of pterygium growth into the patient's line of sight thereby limiting the need for surgery and improving quality of life for patients with pterygia.

Conditions

• Pterygium

Interventions

Type	Name	Description
DRUG	local injection of bevacizumab	Upon enrollment into the study: - initial injection of bevacizumab, a 1 week post-injection visit,and monthly visits thereafter for a total of 6 months. At the 1-month and 3-month visit post-injection visit, an additional bevacizumab injection will be offered if pterygium regression has not occurred. All injections of bevacizumab will consist of injecting 0.1mL of a 2.5mg/0.1mL concentration of bevacizumab into the head of the pterygium.

Timeline

• Start date: 2007-08-01
• Primary completion: 2010-03-01
• Completion: 2010-03-01
• First posted: 2008-01-11
• Last updated: 2014-06-04
• Results posted: 2012-06-25

Locations

1 site across 1 country: United States